A preclinical precision medicine biotech company, looking to leverage their genome editing platform technology, was seeking support in narrowing their indication focus. To justify the R&D investment into an initial indication, the company needed a comprehensive commercial analysis of 10 potential indications. Kineticos was also asked to provide a valuation that could be leveraged throughout the fund raising process.
For each indication, Kineticos performed a commercial assessment that included the below components.
- Disease and treatment overview
- Competitive landscape
- Target Product Profiles including minimum market entry and gold standard for:
- Health Economics
- 5-year revenue forecasts
The 10 indication summaries were leveraged to calculate a data-driven company valuation and determine a lead indication, of which both were leveraged in seed round and series A investor meetings.